"Muscle invasive" trang 1 - tải miễn phí từ tailieunhanh
Management of non-muscle-invasive bladder cancer: Quality of clinical practice guidelines and variations in recommendations

Management of non-muscle-invasive bladder cancer: Quality of clinical practice guidelines and variations in recommendations
12    114    0
Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities

Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities
9    96    0
Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer

Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
9    67    0
Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: A phase II trial

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: A phase II trial
6    81    1
Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: Case report of an unexpected response

Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: Case report of an unexpected response
4    71    1
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
9    75    1
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer
9    83    1
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier

Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier
18    83    1
Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies

Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies
15    34    1
Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: A retrospective non-randomized comparative study

Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: A retrospective non-randomized comparative study
11    50    1
Quantitative MRI comparison of multifidus muscle degeneration in thoracolumbar fractures treated with open and minimally invasive approach

Quantitative MRI comparison of multifidus muscle degeneration in thoracolumbar fractures treated with open and minimally invasive approach
6    58    1
Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: A multicenter retrospective study

Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: A multicenter retrospective study
8    26    1
Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: Longitudinal expression, transcriptome-level effects and modulation of chemosensitivity

Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: Longitudinal expression, transcriptome-level effects and modulation of chemosensitivity
15    16    1
Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer
11    1    1
Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: A comparison of two sequencing methods and gene sets using FFPE specimens

Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: A comparison of two sequencing methods and gene sets using FFPE specimens
10    5    1
The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
7    3    1
Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis

Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis
12    6    1
Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer

Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
6    65    0
Down-regulation of A-FABP predicts nonmuscle invasive bladder cancer progression: Investigation with a long term clinical follow-up

Down-regulation of A-FABP predicts nonmuscle invasive bladder cancer progression: Investigation with a long term clinical follow-up
13    55    1
Comparison of serum markers for muscle damage, surgical blood loss, postoperative recovery, and surgical site pain after extreme lateral interbody fusion with percutaneous pedicle screws or traditional open posterior lumbar interbody fusion

Comparison of serum markers for muscle damage, surgical blood loss, postoperative recovery, and surgical site pain after extreme lateral interbody fusion with percutaneous pedicle screws or traditional open posterior lumbar interbody fusion
7    33    1